by Steven A. Grossman | Sep 15, 2025 | Uncategorized
This week’s questions:Is Secretary Kennedy at risk of losing his job?What is Kenvue? Doesn’t J&J make Tylenol?How realistic is it to dramatically shorten product review cycles? ———Q: Is Secretary Kennedy at risk of losing his job? A: Many...
by Steven A. Grossman | Sep 7, 2025 | Uncategorized
This week’s questions:What’s at stake when a CDC director won’t sign off on the Administration’s vaccine policies, is fired, and several senior center leaders resign? What happens next at CDC?What are the possible impacts of the CDC situation on FDA and...
by Steven A. Grossman | Sep 5, 2025 | Short Takes and Updates
FDA Matters doesn’t cover the news….we provide analysis of what’s behind the newsThis week: My Comment on Secretary Kennedy’s September 4 Appearance Before the Senate Finance CommitteeMAHA Strategy Plan Likely to Be Released Week of September 8.MAHA...
by Steven A. Grossman | Sep 2, 2025 | Uncategorized
———This week’s questions:Did your column on MAHA intend to deliver a specific message to journalists and lead advocacy groups? What is the most critical FDA issue in September? What are some FDA issues that are simmering and will eventually surface?...
by Steven A. Grossman | Aug 28, 2025 | Short Takes and Updates
For much of the past 20 years, my primary professional responsibility has been to impress upon lawmakers, the media, and stakeholders that FDA’s value far exceeds its budget. Sometimes, I would emphasize the economics — FDA oversees goods and services that total...
